STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLB
  4. [Form 4] Core Laboratories Inc. Insider Trading Activity

Core Labs Insider Mark Tattoli Nets Additional Shares in Routine Vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Form 4 filed on 08/05/2025 discloses two insider transactions by Mark D. Tattoli, Senior VP, General Counsel & Secretary of Core Laboratories Inc. (CL​B).

  • Exercise of Restricted Shares (Code M): 250 common shares were acquired at $0 on 08/01/2025 as previously granted restricted stock vested. Beneficial ownership rose to 16,393.621 direct shares after the exercise.
  • Tax Withholding (Code F): 99 shares were withheld at $10.53 per share to satisfy tax obligations related to the vesting event.

Net result is an increase of 151 direct shares. The filer also reports 20 shares held in a custodial account and 1,694.842 shares in the company 401(k) plan. Following the transactions, Tattoli continues to hold 2,150 unvested restricted shares with multi-year vesting schedules.

No open-market sales or purchases occurred; activity reflects routine vesting and associated tax withholding. Given the small size relative to CLB’s float and market capitalization, the filing is immaterial to the company’s valuation but provides insight into ongoing equity compensation for senior management.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine vesting; minor net share increase, negligible market impact.

The Form 4 details standard equity-compensation mechanics: 250 restricted shares vested, 99 withheld for taxes. Net addition of 151 shares shows no bearish intent—there were no discretionary sales. Remaining 2,150 unvested shares continue to align the SVP’s incentives with shareholders. Transaction size (< 0.001% of CLB’s float) and $1.1k gross value are far below materiality thresholds. Consequently, the disclosure is governance-related rather than valuation-relevant. I classify the impact as neutral.

Insider Tattoli Mark Damian
Role SVP, Gen Counsel & Secretary
Type Security Shares Price Value
Exercise Restricted Shares 250 $0.00 --
Tax Withholding Common Stock 99 $10.53 $1K
Exercise Common Stock 250 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Shares — 2,150 shares (Direct); Common Stock — 16,294.621 shares (Direct); Common Stock — 20 shares (Indirect, Custodial account)
Footnotes (1)
  1. The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date. Multiple restricted share grants are included in this total.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tattoli Mark Damian
(Last) (First) (Middle)
6316 WINDFERN ROAD
(Street)
HOUSTON TX 77040
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Gen Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2025 F 99 D $10.53 16,294.621 D
Common Stock 08/01/2025 M 250 A $0 16,393.621 D
Common Stock 20 I Custodial account
Common Stock 1,694.842 I 401 (k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Shares (1) 08/01/2025 M 250 (1) (1) Common Stock 250 $0 2,150(2) D
Explanation of Responses:
1. The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.
2. Multiple restricted share grants are included in this total.
/s/ Mark D. Tattoli 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Core Laboratories (CLB) shares did Mark D. Tattoli acquire?

250 restricted shares vested and were added to his direct holdings on 08/01/2025.

Were any CLB shares sold on the open market in this Form 4?

No. 99 shares were withheld by the company at $10.53 solely for tax purposes; no market sale occurred.

What is Tattoli’s total direct ownership after the transactions?

He now directly owns 16,393.621 CLB shares, plus indirect holdings in a custodial account and 401(k).

How many unvested restricted shares does the insider still hold?

The filing states a remaining balance of 2,150 unvested restricted shares subject to future vesting.

Does this insider transaction materially affect Core Laboratories’ stock outlook?

Given the small share count and routine nature, the impact on CLB’s valuation is considered immaterial.